This indirectly suggested that SRC overexpression might act as an essential compensatory mechanism for the loss of EPHB6 in cancer cells, indicating that the SL interaction of EPHB6 and SRC may represent a promising therapeutic target. This evidence concerns the gene EPHB6 and cancer.